MONTREAL and MUNICH, Germany, March 17, 2023 (GLOBE NEWSWIRE) — TVM Capital Life Science (“TVM”), a major international venture capital firm focused on investments in life sciences innovation, these days announced that Dr. Luc Marengère, Managing Companion, and Dr. Sascha Berger, Common Companion of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings collectively major innovators, active investors and committed strategics from the medtech industry to companion and develop subsequent-generation healthcare technologies. The conference will take spot March 20-23, 2023, in Dana Point, California, USA.

“Medtech innovation plays a pivotal function in the healthcare ecosystem and has the prospective to revolutionize the sector by enhancing patient outcomes, rising efficiency, and minimizing charges. A single important element of our approach is to invest in disruptive, breakthrough, industrial-stage technologies that map important future trends and considerably transform existing common-of-care. In addition to connecting with fellow investors and dealmakers to go over marketplace possibilities and requirements, we appear forward to meeting young, hugely revolutionary corporations at the LSI Summit to additional expand TVM’s robust medtech portfolio,” stated Dr. Luc Marengère.

TVM pursues a distinctive two-pronged approach, investing in differentiated health-related technologies with industrial proof-of-idea and late clinical-stage therapeutics as effectively as financing revolutionary early-stage therapeutics by way of a single asset firm strategy (Project-Focused Enterprise, PFC) that leverages TVM’s strategic partnership with worldwide pharmaceutical firm, Eli Lilly and Enterprise. With its late-stage medtech investments, the Enterprise focuses on revolutionary enterprises from North America or the EU operating to transform health-related practice with their groundbreaking devices and technologies.

Dr. Sascha Berger added: “TVM’s track record of effective collaboration highlights our partnership and worth-developing strategy with innovators. As accurate partners, we perform closely with our portfolio corporations, striving to have an understanding of their tips, and locate techniques to advance their innovations to accelerate development, facilitate marketplace expansion and eventually aid them come to be or continue to be a leader in their respective markets. With our existing fund TVM Life Science Innovation II, we continue to expand our approach, that has been validated by way of a quantity of corporations in each Fund I and II, to develop a portfolio of differentiated goods with robust leadership teams.”

Investment highlights from TVM’s medtech industrial-stage portfolio consist of:

• Access Vascular Inc. has created and commercializes award-winning intravenous catheters addressing the most widespread and pricey complications of intravenous therapy: infection, thrombosis, and phlebitis. Engineered to mimic the body’s all-natural chemistry, Access Vascular catheters are made to evade foreign physique response and associated complications.
• Egg Health-related has created and commercializes a lab radiation protection method that significantly reduces scatter radiation exposure through interventional angiographic procedures. During an X-ray, radiation reflects off a patient and scatters to any person else in the area. This benefits in an improved danger of cancer chromosomal abnormalities, skin harm and eye injury for healthcare pros in this field. EGGNEST™ reduces scatter radiation exposure by 91% for the complete group devoid of interrupting the workflow.
• Emovi’s technologies and AI options address clinical challenges that exist by way of the continuum of care for sufferers with knee discomfort and pathology. The Enterprise has created the only FDA cleared, Wellness Canada licensed and CE Marked health-related device to assess the 3D motion of the knee and have an understanding of what is taking place in patient’s knee in order to far better recognize causes of symptoms and propose a effective care strategy.
• Kent Imaging, a major innovator in close to-infrared tissue oxygenation imaging, develops, manufactures, and markets health-related technologies that supports genuine-time selection-producing in wound care, vascular and surgical subspecialties and tracks the healing approach. Kent Imaging targets limb preservation and reconstructive surgical markets – locations with clear unmet have to have, as non-healing wounds are a main burden to sufferers and the healthcare method.
• Panthera Dental, a planet leader in CAD/CAM implant options and dental sleep appliances, has effectively combined creativity, science and know-how to bring to marketplace its proprietary revolutionary technologies to provide subsequent-generation goods to the dental sector as effectively as a novel innovation to treat sleep apnea. The Enterprise just not too long ago launched a new solution: The Magnet-XTM, the world’s initially removable magnetic implant bar providing steady forces, lateral guidance and stability and straightforward handling for sufferers with significantly less dexterity.

About TVM Capital Life Science
TVM Capital Life Science (“TVM”) is a major international venture capital firm focused on investing in life science innovations. The Enterprise has a hugely skilled transatlantic investment group and about $900 million below management. TVM’s portfolio focuses on therapeutics and health-related technologies from North America and the EU that represent differentiated initially-in-class or ideal-in-class assets with the prospective to transform common of care.

TVM pursues a distinctive two-pronged approach, financing revolutionary early-stage therapeutics by way of a single asset firm strategy (Project-Focused Enterprise, PFC) that leverages the firm’s strategic partnership with worldwide pharmaceutical firm, Eli Lilly and Enterprise. TVM also invests in differentiated industrial-stage health-related technologies and late clinical-stage therapeutics.

With its late-stage investments, TVM focuses on differentiated health-related technologies with industrial proof-of-idea as effectively as late-stage therapeutics anticipated to immediately attain main improvement or regulatory milestones. This approach has been validated by way of a quantity of corporations in each Fund I and II and the Colucid Pharmaceuticals exit.

The TVM investment group has worked collectively for more than a decade to efficiently use this revolutionary strategy to maximize returns for investors and finance new therapies and technologies to meaningfully increase patient lives.

Media Relations

MC Solutions AG

Europe: Anne Hennecke
Tel: +49 211 529 252 22
North America: Laurie Doyle
Tel: +1 339 832 0752
E-mail: tvm@mc-solutions.eu